3 results
The primary objective of this study is to determine whether LY2484595, administered incombination with atorvastatin for 12 weeks to patients with hypercholesterolemia or low HDL-C, will significantly increase mean HDL-C and decrease mean LDL-C from…
To compare the progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing) with those treated with placebo.
The Primary objective is to confirm the maintenance of vigilance with SENS-111.Secondary objectives are:* to confirm the maintenance of working memory, and cognitive function; * to confirm the pharmacodynamics effect of SENS-111 on symptoms…